Vertically Integrated Hemp/CBD Player Sweet Earth Holdings Debuts on CSE
Source: Peter Epstein for Streetwise Reports  (5/26/20)
With CBD showing some promise against Covid-19 and cannabis stocks rising, Peter Epstein of Epstein Research discusses the market with Sweet Earth Holdings executives. More >

Surface Oncology Shares Trade Up 40% on Phase 1 Study Plans for SRF617 Combined with Merck's KEYTRUDA
Source: Streetwise Reports  (5/20/20)
Shares of Surface Oncology set a new 52-week high price after the company reported that it is partnering with Merck & Co. in an immuno-oncology study of SRF617, targeting CD39 in combination with KEYTRUDA® (pembrolizumab) in solid tumor patients. More >

US Biopharma to Launch Phase 3 Trial in Bacterial Vaginosis
Source: Streetwise Reports  (5/20/20)
Daré Bioscience's study, its prospects and the indication's U.S. market opportunity are discussed in a ROTH Capital Partners report. More >

Arbutus Biopharma Trades 25% Higher on Phase 1 Hepatitis B Results
Source: Streetwise Reports  (5/19/20)
Shares of Arbutus Biopharma traded higher after the company reported significant and continuous reduction in HBsAg in 12 chronic hepatitis B subjects using 60 mg dosage of its AB-729 drug. More >

Moderna Shares Rise 25% on Positive Phase 1 Coronavirus Vaccine Trial Data
Source: Streetwise Reports  (5/18/20)
Shares of Moderna Inc. traded higher, setting a new 52-week high price, after the firm reported positive interim results in its Phase 1 study of mRNA Vaccine (mRNA-1273) against SARS-CoV-2. More >

Biopharma Seeks Ethics Approval in Australia to Test COVID-19 Treatment
Source: Streetwise Reports  (5/18/20)
Algernon Pharmaceuticals intends to test a repurposed drug for this indication, in a trial in three countries. More >

Cannabis Cultivator Shifts Focus to Commercializing Technology
Source: Streetwise Reports  (5/18/20)
Sproutly Canada has received capital investment from Infusion Biosciences. More >

Biotech Expands Antibody Research Across Multiple Neurodegenerative Diseases and Covid-19
Source: Streetwise Reports  (5/14/20)
ProMIS Neurosciences advances its various antibody programs related to neurodegenerative diseases and viral infections such as Covid-19. More >

Allogene Therapeutics Shares Climb 30% on Phase 1 Relapsed/Refractory NHL Study Data
Source: Streetwise Reports  (5/14/20)
Shares of Allogene Therapeutics traded higher and reached a new 52-week high price after the company reported initial results from its Phase 1 relapsed/refractory non-Hodgkin lymphoma trial. More >

Acceleration of COVID-19 Vaccine Programs Could Benefit U.S. Biotech
Source: Streetwise Reports  (5/13/20)
The development timeline for Inovio Pharmaceuticals' coronavirus vaccine candidate is discussed in an H.C. Wainwright & Co. report. More >

MyoKardia Shares Get a Jolt from Positive Phase 3 HCM Clinical Trial Results
Source: Streetwise Reports  (5/11/20)
Shares of MyoKardia traded 60% higher, setting a new 52-week high price, after the company reported that it met all primary and secondary endpoints in the Phase 3 EXPLORER study of mavacamten in treatment of obstructive hypertrophic cardiomyopathy. More >

Pharmaceutical Firm Gains Ethics Approval for Phase 2 Human IPF and Chronic Cough Trial
Source: Streetwise Reports  (5/10/20)
Algernon Pharmaceuticals reported that it has received ethics approval in Australia for a Phase 2 human clinical study of NP-120 (Ifenprodil) for use in treatment of idiopathic pulmonary fibrosis and chronic cough. More >

Protagonist's Shares Nearly Double After Reporting Q1 Earnings and Positive Phase 2 Trial Results
Source: Streetwise Reports  (5/8/20)
Shares of Protagonist Therapeutics traded higher and reached a new 52-week high price after the company released Q1/20 financial results and positive data from its Phase 2 study of PTG-300 in patients with polycythemia vera, a type of blood cancer. More >

Building a Better Covid-19 Antibody Test
Source: Streetwise Reports  (5/6/20)
ProMIS is harnessing its unique technology platform to develop a more error-free antibody test. More >

California Biotech Partners for Manufacture of COVID-19 Vaccine Candidate
Source: Streetwise Reports  (5/6/20)
Arcturus Therapeutics Holdings' arrangement is explained and commented on in an H.C. Wainwright & Co. report. More >

Biotech Develops Antagonists for Protein Tied to Neurodegenerative Diseases
Source: Streetwise Reports  (5/6/20)
ProMIS Neurosciences' antagonists prevent dysfunctional protein aggregation. More >

Horizon Therapeutics Shares Rise 15% on Strong Q1 Results and Raised F/Y Sales Guidance
Source: Streetwise Reports  (5/6/20)
Shares of Horizon Therapeutics traded higher setting a new 52-week high price after the company reported a 27% y-o-y increase in net sales for Q1/20 and raised FY/20 net sales guidance. More >

Alexion's Buyout of Portola Pharmaceuticals Gets Investors' Blood Flowing
Source: Streetwise Reports  (5/5/20)
Shares of Portola Pharmaceuticals traded 130% higher after the company reported that it has received an $18 per share buyout offer from Alexion Pharmaceuticals. More >

Firm Creates Novel Intrabodies for ALS and Other Neurodegenerative Diseases
Source: Streetwise Reports  (5/4/20)
ProMIS Neurosciences reported it has generated novel intrabodies that are highly selective for misfolded forms of TAR DNA-binding protein 43 implicated in several neurologic disorders. More >

Stemline Shares Take Off on $677 Million Buyout Offer by Global Pharmaceutical Firm
Source: Streetwise Reports  (5/4/20)
Shares of Stemline Therapeutics traded 150% higher after the company reported that it has entered into a definitive agreement to be acquired by Italy's Menarini Group in a deal valued at up to $677 million. More >

Seattle Genetics Shares Trade Higher on Q1/20 Earnings and 22% Growth in ADCETRIS Sales
Source: Streetwise Reports  (5/1/20)
Seattle Genetics shares traded 8% higher, reaching a new 52-week high, after the company reported Q1/20 financial results which included a 10% y-o-y increase in net revenues fueled by a 22% increase in sales of ADCETRIS® and a strong debut for PADCEVâ„¢ in its first full quarter of sales. More >

Biotech Cleared for Phase 2b/3 Trial of NMDA Receptor Antagonist for COVID-19 Patients in Canada
Source: Streetwise Reports  (4/30/20)
Algernon Pharmaceuticals reported it received approval from Health Canada for a Phase 2b/3 multinational clinical study of Ifenprodil in COVID-19 patients to prevent progression to intubation and mechanical ventilation. More >

Chimerix Shares Rise 50% as FDA Gives 'Go Ahead' for Phase 2/3 ALI Study in COVID-19 Patients
Source: Streetwise Reports  (4/29/20)
Shares of Chimerix Inc. traded higher after the company reported it has received U.S. FDA clearance to initiate a Phase 2/3 Study of dociparstat sodium in acute lung injury for patients afflicted with severe COVID-19. More >

Avadel Shares Rise and Shine on Positive Phase 3 Narcolepsy Study Findings
Source: Streetwise Reports  (4/27/20)
Avadel Pharmaceuticals' shares traded 25% higher reaching a new 52-week high price after the company reported positive topline results from its Pivotal Phase 3 REST-ON trial of FT218 for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients. More >

Mesoblast Shares Soar 120% After Reporting 83% Survival Rate in COVID-19 Patients with ARDS
Source: Streetwise Reports  (4/24/20)
Shares of Mesoblast more than doubled and set a new 52-week high price after the company reported that it achieved a 83% survival rate in New York ventilator-dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome who were treated with its allogeneic cell therapy remestemcel-L. More >